“There are currently insufficient data available to assess the vaccine efficacy from 65 years of age,” the committee, also known as Stiko, said in a draft resolution made available by the German health ministry on Thursday.
“The AstraZeneca vaccine, unlike the mRNA vaccines, should only be offered to people aged 18-64 years at each stage,” it added.
Stiko’s assessment was based on the same trial data published by medical journal The Lancet on Dec 8.
The European Union approved a vaccine developed by Pfizer and its German partner BioNTech in late December, and gave the green light to a shot made by Moderna in early January.
AstraZeneca did not immediately respond to a request for comment.
